EULAR 2023

Risk factors and prevention of arthritis

Treatment opportunities and what is new in PsA

Let's go for early treatment in axial envolvement?

Systemic inflammation in SpA /PsA

Definition of early axSpA

Clinically relevant findings for SpA detection

Do NSAIDs modify the appearance of SIJ MRI?

What is early axSpA?

Secukinumab vs Adalimumab on radiographic progression…

Should we follow chronic back pts. suspected of early…

The effect of IL-17 inhibition on radiographic…

Factors associated with remission in early peripheral…

Data from clinical studies relevant for daily practice

Qual'e lo strumento ideale per la valutazione di…

Facteurs associés à l’obtention d’une rémission dans la…

Secukinumab vs Adalimumab dans la progression…

Los AINES modifican la expresión de la RM de…

Effekt der IL-17 Inhibition auf die Röntgenprogression

Was ist frühe axSpA?

Daten aus klinischen Studien für die tägliche Praxis

Deberíamos seguir a los pacientes con dolor lumbar…

Definition consensuelle ASAS de la spondyloarthrite…

MTX + Biologica in PsA

Systemic inflammation objectively detectable

Differences between sex and gender in PsA

Dual inhibition of IL-17A and IL-17F: a new option in…

Higher comorbiditiy burden in PsA vs RA

Early therapy in PsA is predictive

No need of MTX again and again and...

Points to consider in PsA!

Sytemische Inflammation objektiv erkennbar

MTX + Biologica bei PsA

Frühe Therapie bei PsA prädiktiv

Deucravacitinib - effektiv und sicher

Differenze di genere nell'Artrite Psoriasi

Nicht schon wieder MTX...

Points to consider bei PsA

Duale Inhibition A und F: neue Option für PsA

Putting a focus on TDM

Keeping an eye on the lung!

Update on JAKi safety

Pushing the brake with a new treatment strategy

Peresolimab - a new therapeutic principle in…

Pooled safety analysis of filgotinib

The IL-23 pathway

What is new in RA?

Major adverse cardiovascular events in patients on…

Difficult to treat and poly-refractory RA in a clinical…

Lung involvement in RA

Corticoid bridging in RA - useful and safe

Tratamiento con glucocorticoides al inicio del FAME -…

AR difícil de tratar y polirrefractaria en la practica…

Kardiovaskulære hendelser hos pasienter behandlet med…

Development of EMM in SpA patients treated with…

Overview of treatment recommendations in PsA and axSpA

Immunogenicity in Adalimumab - real-world data

Measurement of anti-drug antibodies in rheumatology

To stop or not to stop TNF-inhibitors after pregnancy…

Incidence of ILD in patients with RA and PsA

Immunogenisitet hos pasienter behandlet med adalimumab…

Interrompere o non interrompere gli anti-TNF dopo la…

Aspetti principali delle raccomandazioni per l'Artrite…

Insidens av interstitiell lungesykdom hos pasienter med…

Messung von Anti-drug Antibodies in der Rheumatologie

Therapie der Arthritis unter Checkpoint-Inhibitoren

Childhood infections, perinatal factors, and the risk…

Infezioni infantili, fattori perinatali e rischio di…

Update on CAR-T cells!

JAK inhibition and BTK-JAK inhibition in lupus

Telitacicept in lupus

1-Jahres Daten zur CAR-T-Zell Therapie beim Lupus

Aktuelles zur CAR-T-Zelltherapie!

Telitacicept beim Lupus

IL-17 isoforms in enthesitis